Decreased Matriptase/HAI-1 Ratio in Advanced Colorectal Adenocarcinoma of Chinese Patients

Wen-Chiuan Tsai；Lai-Fa Sheu；You-Chen Chao；Ann Chen；Hung Chiang；Jong-Shiaw Jin

colorectal adenocarcinoma ； HAI-1 ； immunohistochemistry ； matriptase ； microarray

The Chinese Journal of Physiology

50卷5期（2007 / 10 / 31）

225 - 231

英文

Matriptase is a serine protease expressed by tumors of surface epithelial origin. We tested the expressions of matriptase and hepatocyte growth factor activator inhibitor-1 (HAI-1) maybe associated with the progression of colorectal adenocarcinoma. Immunohistochemical analysis of matriptase and HAI-1 was performed in tissue microarray slides of 91 colorectal adenocarcinomas with various degrees. The matriptase scores in moderately (346.7±10.6) and poorly differentiated (248.1±12.9) were significantly lower than those in well differentiated (368.4±9.6) colorectal adenocarcinomas. The matriptase/HAI-1 ratios in poorly (1.8±0.4) and moderately differentiated (1.8±0.3) were significantly lower than in well differentiated (2.2±0.2) colorectal adenocarcinomas. Otherwise, the matriptase scores and matriptase/HAI-1 ratio showed significant reverse correlation with more advanced TNM stages of colorectal adenocarcinomas in Chinese patients. In conclusion, pharmacological inhibitors of matriptase may not be effective treatment for advanced colorectal adenocarcinomas.

1. Aimes, R.T.,Zijlstra, A.,Hooper, J.D.,Ogbourne, S.M.,Sit, M.L.,Fuchs, S.,Gotley, D.C.,Quigley, J.P.,Antalis, T.M.(2003).Endothelial cell serine protease expressed during vascular morphogenesis and angiogenesis.Thromb. Hemost.,89,561-572.
2. Allegra, C.J.,Paik, S.,Colangelo, L.H.,Parr, A.L.,Kirsch, I.,Kim, G.,Klein, P.,Johnston, P.G.,Wolmark, N.,Wieand, H.S.(2003).Prognostic value of thymidylate synthase, Ki67, and p53 in patients with Dukes B and C colon cancer: a national cancer institutenational surgical adjuvant breast and bowel project collaborative study.J. Clin. Oncol.,21,241-250.
3. Arber, N.,Hibshoosh, H.,Yasui, W.,Neugut, A.I.,Hibshoosh, A.,Yao, Y.,Sgambato, A.,Yamamoto, H.,Shapira, I.,Rosenman, D.,Fabian, I.,Weinstein, I.B.,Tahara, E.,Holt, P.R.(1999).Abnormalities in the expression of cell cycle-related proteins in tumors of the small bowel.Cancer Epiderm. Biomar,8,1101-1105.
4. Benaud, C.,Dickson, R.B.,Lin, C.Y.(2001).Regulation of the activity of matriptase on epithelial cell surfaces by a blood-derived factor.Eur. J. Biochem.,268,1439-1447.
5. Cagir, B.,Nagy, M.W.,Topham, A.,Rakinic, J.,Fry, R.D.(1999).Adenosquamous carcinoma of the colon, rectum, and anus: epidemiology, distribution, and survival characteristics.Dis. Colon Rectum.,42,258-263.
6. Cerottini, J.P.,Caplin, S.,Pampallona, S.,Givel, J.C.(1999).Prognostic factors in colorectal cancer.Oncol. Rep.,6,409-414.
7. Cheng, M.F.,Tzao, C.,Tsai, W.C.,Lee, W.H.,Chen, A.,Chiang, H.,Sheu, L.F.,Jin, J.S.(2006).Expression of EMMPRIN and matriptase in esophageal squamous cell carcinoma: Correlation with clinicopathological parameters.Dis. Esophagus,19,482-486.
8. Connolly, K.C.,Gabra, H.,Millwater, C.J.,Taylor, K.J.,Rabiasz, G.J.,Watson, J.E.,Smyth, J.F.,Wyllie, A.H.,Jodrell, D.I.(1999).Identification of a region of frequent loss of heterozygosity at 11q24 in colorectal cancer.Cancer Res.,59,2806-2809.
9. Ferrara, N.(1995).The role of vascular endothelial growth factor in pathological angiogenesis.Breast Cancer Res. Treat,36,127-137.
10. Folkman, J.(1990).What is the evidence that tumors are angiogenesis dependent?.J. Natl. Cancer Inst,82,4-6.
11. Gabra, H.,Watson, J.E.,Taylor, K.J.,Mackay, J.,Leonard, R.C.,Steel, C.M.,Porteous, D.J.,Smyth, J.F.(1996).Definition and refinement of a region of loss of heterozygosity at 11q23.3-q24.3 in epithelial ovarian cancer associated with poor prognosis.Cancer Res.,56,950-954.
12. Gentile, M.,Wiman, A.,Thorstenson, S.,Loman, N.,Borg, A.,Wingren, S.(2001).Deletion mapping of chromosome segment 11q24-q25, exhibiting extensive allelic loss in early onset breast cancer..Int. J. Cancer,92,208-213.
13. Hemilton, S.R.,Aaltonen, LA.(2000).WHO classification of tumors: tumors of the digestive system.Lyon:IRAC press.
14. Jacquemier, J.,Ginestier, C.,Bertucci, F.,Jauffret, E.C.,Geneix, J.,Birnbaum, D.(2003).Tissue microarrays: a powerful tool in transfer and quality control in oncology, Bulletin.Du. Cancer,90,31-38.
15. Jin, J.S.,Chen, A.,Hsieh, D.S.,Yao, C.W.,Cheng, M.F.,Lin, Y.F.(2006).Expression of serine protease matriptase in renal cell carcinoma: correlation of tissue microarray immunohistochemical expression analysis results with clinicopathological parameters.Int. J. Surg. Pathol.,14,65-72.
16. Jin, J.S.,Cheng, T.F.,Tsai, W.C.,Sheu, L.F.,Chiang, H.,Yu, C.P.(2007).Expression of the serine protease, matriptase, in breast ductal carcinoma of Chinese women: correlation with clinicopathological parameters.Histol. Histopathol,22,305-309.
17. Jin, J.S.,Hsieh, D.S.,Loh, S.H.,Chen, A.,Yao, C.W.,Yen, C.Y.(2006).Increasing expression of serine protease matriptase in ovarian tumors: tissue microarray analysis of immunostaining score with clinicopathological parameters..Mod. Pathol,19,447-452.
18. Jin, X.,Hirosaki, T.,Lin, CY.(2005).Production of soluble matriptase by human cancer cell lines and cell surface activation of its zemogen by trypsin.J. Cell. Biochem.,95,632-647.
19. Kataoka, H.,Hamasuna, R.,Itoh, H.,Kitamura, N.,Koono, M.(2000).Activation of hepatocyte growth factor/scatter factor in colorectal carcinoma.Cancer Res.,60,6148-6159.
20. Lam, J.S.,Belldegrum, A.S.,Figlin, R.A.(2004).Tissue array-based predictions of pathobiology, prognosis and response to treatment for renal cell carcinoma therapy.Clin. Cancer Res,10,6304-6309.
21. Lee, J.W.,Song, S.Y.,Choi, J.J.,Lee, S.J.,Kim, B.G.,Park, C.S.,Lee, J.H.,Lin, C.Y.,Dickson, R.B.,Bae, D.S.(2005).Increased expression of matriptase is associated with histopathologic grades of cervical neoplasia.Hum. Pathol.,36,626-633.
22. Lee, M.S.,Kiyomiya, K.I.,Benaud, C.,Dickson, R.B.,Lin, C.Y.(2005).Simultaneous activation and hepatocyte growth factor activator inhibitor 1-mediated inhibition of matriptase induced at activation foci in human mammary epithelial cells.Am. J. Physiol. Cell Physiol.,288,932-941.
23. Lee, S.L.,Dickson, R.B.,Lin, C.Y.(2000).Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease.J. Biol. Chem.,275,36720-36725.
24. McKay, J.A.,Douglas, J.J.,Ross, V.G.,Curran, S.,Ahmed, F.Y.,Loane, J.F.,Murray, G.I.,McLeod, H.L.(2000).Expression of cell cycle control proteins in primary colorectal tumor does not always predict expression in lymph node metastases.Clin. Cancer Res.,6,1113-1118.
25. Oberst, M.,Anders, J.,Xie, B.,Singh, B.,Ossandon, M.,Johnson, M.,Dickson, R.B.,Lin, C.Y.(2001).Matriptase and HAI-1 are expressed by normal and malignant epithelial cells in vitro and in vivo..Am. J. Pathol.,158,1301-1311.
26. Oberst, M.D.,Johnson, M.D.,Dickson, R.B.,Lin, C.Y.,Singh, B.,Stewart, M.,Williams, A.,Awatif, A.N.,Smyth, J.F.,Gabra, H.,Sellar, G.C.(2002).Expression of the serine protease matriptase and its inhibitor HAI-1 in epithelial ovarian cancer: correlation with clinical outcome and tumor clinicopathological parameters.Clin. Cancer Res,8,1101-1107.
27. Oberst, M.D.,Singh, B.,Ozdemirli, M.,Dickson, R.B.,Johnson, M.D.,Lin, C.Y.(2003).Characterization of matriptase expression in normal human tissue.J. Histochem. Cytochem,51,1017-1025.
28. Petersen, S.,Thames, H.D.,Nieder, C.,Petersen, C.,Baumann, M.(2001).The results of colorectal cancer treatment by p53 status: a treatment-specific overview.Dis. Colon Rectum,44,322-334.
29. Potter, J.D.(1999).Colorectal cancer: molecules and population.J. Natl. Cancer Inst.,91,916-932.
30. Sasaki, S.,Masaki, T.,Umetani, N.,Futakawa, N.,Ando, H.,Muto, T.(1998).Characteristics in primary signet-ring cell carcinoma of the colorectum, from clinicopathological observation.Jpn. J. Clin. Oncol.,28,202-206.
31. Takeuchi, T.,Harris, J.L.,Huang, W.,Yan, K.W.,Coughlin, S.R.,Craik, C.S.(2000).Cellular localization of membrane-type II serine protease 1 and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogen activator as substrates.J. Biol. Chem.,275,26333-26342.
32. Thomas, G.V.,Szigeti, K.,Murphy, M.,Draetta, G.,Pagano, M.,Loda, M.(1998).Down-regulation of p27 is associated with development of colorectal adenocarcinoma metastases.Am. J. Pathol.,153,681-687.
33. Tsai, W.C.,Chao, Y.C.,Lee, W.H.,Chen, A.,Sheu, L.F.,Jin, J.S.(2006).Increasing EMMPRIN and matriptase expression in hepatocellular carcinoma: tissue microarray analysis of immunohistochemical scores with clinicopathological parameters.Histopathology,49,388-395.
34. Zhang, Y.,Cai, X.,Schlegelberger, B.,Zheng, S.(1998).Assignment1 of human putative tumor suppressor genes ST13 (alias SNC6) and ST14 (alias SNC19) to human chromosome bands 22q13 and 11q24->q25 by in situ hybridization.Cytogenet. Cell Genet.,83,56-57.